Medis is a leader in pharmaceutical development and out licensing, offering a broad portfolio of quality pharmaceutical products and comprehensive registration dossiers and intellectual property since 1985. Medis is a powerful partner with a proven track record in securing regulatory approval prior to patent expiries, and has obtained marketing authorizations in over 140 countries to date. We out-license products from the pipeline of our parent company, Teva. Medis ehf is 100% owned by Teva Pharmaceutical Industries Ltd (NYSE, TASE: TEVA).

We offer:
•Dossiers with product supply for generic products for all major therapeutic categories
•Full launch coordination to ensure customers timely Day-1 launches to market
•High quality generic products and registration dossiers according to current EU standards (CTD)
•Extensive generic portfolio with more than 150 dossiers and around 800 available licenses
•Single-point-of-contact customer experience for all supply related matters
•Ensured flow of goods from 3rd party manufacturing to Medis customers
•State-of-the-art EU-GMP approved sites, primarily in Europe
•Granted MAs available in multiple markets for local marketing or MRP purposes
•Strong development pipeline, enabling the timely availability of new products

We are interested in:
•Out-licensing and supply agreements for all products in our portfolio
•All Territories

We are not interested in:
•Raw materials
•In-licensing
•Herbal medicines, Vitamin preparations or Dietary supplements

Related Categories

Sales Markets

Middle East Region (e.g. UAE); Oceania; North America (USA, Canada); Africa; Central America (e.g. Mexico); East Asia (e.g. China, Japan, Korea); Europe - EU countries; Europe - non EU (e.g. UK, Russia, ex-CIS countries); South America (e.g. Brazil, Colombia); South Asia (e.g. India, Pakistan, Sri Lanka); South East Asia (e.g. Thailand, Philippines, Singapore)